H2 Medical Technologies, part of the H2 Global Group, has created the world’s first functional medical device using hydrogen designed for clinical trials focused on preventing and treating Alzheimer’s disease. This breakthrough comes at a critical time when more than 6.5 million Americans and over 50 million people worldwide are affected by Alzheimer’s and other dementias. The World Health Organization warns that by 2050, these numbers could triple, posing a severe challenge to families and healthcare systems globally. Despite years of research, no effective treatment has been available until now.
Health Technology Insights: Robotics Cuts Cell Therapy Costs 74% at Multiply Labs
David Marsalek, founder and CEO of H2 Global Group, explains that this technology is more than just a concept; it represents the first genuine opportunity to stop Alzheimer’s before symptoms appear and to support those already living with the disease. He emphasized that the company’s mission is to transform decades of scientific research into real hope for millions of families worldwide. Marsalek also shared a broader vision of hydrogen as a fundamental molecule with the potential to improve health across the globe. The company eagerly anticipates upcoming clinical trials to validate the device’s effectiveness.
H2 Global Group plans to showcase this groundbreaking device at LSI Europe 2025 in London, a leading event in the MedTech and HealthTech sectors. This innovation is the result of over thirty years of research and patents developed in collaboration with Professor Shigeo Ohta, a respected authority in molecular hydrogen science and a co-founder of H2 Global Group. Their combined expertise has paved the way for this revolutionary medical advancement.
Health Technology Insights: NextGen Healthcare to Boost Arkansas Palliative Care Growth
Although the initial focus is on Alzheimer’s disease, the potential uses of this hydrogen-based technology extend to other neurological disorders, brain regeneration, and promoting healthy aging. Beyond the medical device, H2 Global Group has introduced consumer products like H2 Premium Water and H2 Brain®, the first two-phase dietary supplement designed to stimulate hydrogen production in the gut microbiome. The company also holds exclusive rights to manufacture hydrogen-based medical devices for veterinary applications. Currently, their hydrogen therapies are being adopted by wellness centers, rehabilitation clinics, dental offices, and elite sports organizations throughout Europe, demonstrating the wide impact of this technology.
Previously funded primarily by Czech investors, H2 Global Group is now inviting partners from the United States and around the world to join during this important phase of growth. The company is moving forward with regulatory approvals in the European Union and plans to seek FDA clearance next, opening access to the largest healthcare market globally. With the Alzheimer’s therapeutics market projected to surpass $20 billion by 2030 and dementia care costs already exceeding $1 trillion annually, H2 Global Group is uniquely positioned as the only provider of functional hydrogen-based therapy. This offers investors a rare opportunity to be part of a rapidly expanding and vital industry.
Health Technology Insights: Nusano Opens New Radioisotope Production Facility
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
